<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prognostic and predictive factors in early, non-metastatic breast cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prognostic and predictive factors in early, non-metastatic breast cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prognostic and predictive factors in early, non-metastatic breast cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Theodoros Foukakis, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonas Bergh, MD, PhD, FRCP (London UK)</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Harold J Burstein, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 09, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H682639939"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The widespread application of adjuvant systemic therapy has reduced mortality from breast cancer in the Western world [<a href="#rid1">1-4</a>]. Unfortunately, many patients are not treated appropriately, with some overtreated (when they would have been cured solely with local therapy) and others undertreated (eg, not treated in the adjuvant setting or treated with drugs that are ultimately not active). It would be of great value to have reliable prognostic factors that could help select those patients most at risk for recurrence. In addition, clinically applicable predictive factors would aid in the personalization of adjuvant therapy by identifying which therapies would be most likely of benefit to patients and which patients would not benefit, potentially sparing them from the unnecessary exposure to potentially toxic and expensive therapies.</p><p>This topic will review prognostic and predictive factors that are relevant for patients diagnosed with early, non-metastatic breast cancer. An overview of the treatment of breast cancer and relevant factors for patients with metastatic breast cancer is discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/737.html" rel="external">"Overview of the treatment of newly diagnosed, invasive, non-metastatic breast cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/767.html" rel="external">"Overview of the approach to metastatic breast cancer"</a>.)</p><p></p><p class="headingAnchor" id="H2002235210"><span class="h1">DEFINITIONS OF PREDICTIVE AND PROGNOSTIC FACTORS</span><span class="headingEndMark"> — </span>The field of marker discovery in oncology is evolving rapidly, driven by the better understanding of tumor biology and knowledge of the human genome. However, only a small proportion of markers have ultimately proven to be clinically useful.</p><p>By definition, a <strong>prognostic</strong> factor is capable of providing information on clinical outcome at the time of diagnosis, independent of therapy. Such markers are usually indicators of growth, invasion, and metastatic potential [<a href="#rid5">5,6</a>]. By contrast, a <strong>predictive</strong> factor is capable of providing information on the likelihood of response to a given therapeutic modality. Such markers are either within the target of the treatment or serve as modulators or epiphenomena related to expression and/or function of the target. Although they can be separately classified, several factors in breast cancer are both prognostic and predictive (eg, the presence of overexpression of the human epidermal growth factor receptor 2 [HER2]).</p><p>Markers that are either predictive or prognostic must demonstrate three factors to be of clinical use [<a href="#rid7">7,8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Analytical validity</strong> – Analytical validity refers to the technical aspects of a test, including accuracy, reproducibility, dependence of pre-analytical issues (eg, the Biospecimen Reporting for Improved Study Quality [BRISQ] recommendations for biospecimens [<a href="#rid9">9</a>]), and reliability.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical validity</strong> – Clinical validity is the ability of a factor to separate a population of interest into two or more subgroups that differ in biologic or clinical outcomes. However, clinical validity does not imply that a factor should be used in direct patient care.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical utility</strong> – Clinical utility implies that a factor is useful for patient care. A factor has clinical utility based on evidence that it impacts outcomes when compared with clinical use without it. Clinical utility requires an assumption of a specific use or context in which the factor is relevant (eg, determination of prognosis in patients with pathologically node-negative cancer).</p><p></p><p>Although high-quality data are preferred in determining clinical utility of a proposed prognostic factor [<a href="#rid10">10</a>], it is now generally agreed that sufficient evidence to support the clinical utility of a proposed marker can be obtained by a retrospective study of prospectively collected material, ideally from randomized clinical trials [<a href="#rid11">11</a>]. This is a time- and cost-effective strategy, compared with the previous requirement of a new trial with the marker as the primary endpoint, which will hopefully yield more promising results.</p><p>In addition, a useful prognostic factor in breast cancer should have the following characteristics [<a href="#rid12">12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>It provides significant and independent prognostic value, validated by clinical testing</p><p class="bulletIndent1"><span class="glyph">●</span>Its determination must be feasible, reproducible, and widely available, with quality control</p><p class="bulletIndent1"><span class="glyph">●</span>The results should be readily interpretable by the clinician</p><p class="bulletIndent1"><span class="glyph">●</span>Measurement must not consume tissue needed for other tests, particularly routine histopathologic evaluation</p><p></p><p class="headingAnchor" id="H1390695845"><span class="h1">PREDICTIVE FACTORS</span><span class="headingEndMark"> — </span>Factors that may enable personalization of adjuvant treatment recommendations are of utmost importance because they would ideally allow for the selection of patients for a particular therapy while sparing others from potentially ineffective therapies. Unfortunately, the identification of clinically useful predictive markers has not been as successful as the identification of prognostic ones. For example, factors traditionally used by many clinicians for the selection of adjuvant therapy were analyzed in a meta-analysis that included over 100,000 patients involved in 123 randomized controlled trials [<a href="#rid1">1</a>]. The report concluded that the relative benefit of adjuvant chemotherapy is independent of age, estrogen receptor (ER) status, grade, tumor size, nodal involvement, and use of adjuvant <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a>.</p><p>The most well-established predictive markers in early breast cancer thus far are the ER (for endocrine therapy) and human epidermal growth factor receptor 2 (for HER2-directed therapy). These are discussed below. Data supporting the predictive role of the Oncotype DX Recurrence Score (RS) in the choice of who should undergo adjuvant chemotherapy (though not what type of therapy they should receive) are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/126631.html" rel="external">"Deciding when to use adjuvant chemotherapy for hormone receptor-positive, HER2-negative breast cancer", section on 'Recurrence Score'</a>.)</p><p class="headingAnchor" id="H2316135149"><span class="h2">ER predicting response to endocrine therapy</span><span class="headingEndMark"> — </span>Estrogen receptor (ER) expression predicts patients who will benefit from endocrine therapy. Although patients with progesterone receptor (PR)-positive tumors also have better outcomes when treated with endocrine therapy, PR status is heavily dependent on ER [<a href="#rid2">2</a>]. Therefore, it does not appear that PR has independently predictive value, especially when the ER status is known [<a href="#rid2">2</a>]. <em>ESR1</em> mutations are an adverse predictive factor for response to endocrine therapy in the metastatic setting, as discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/762.html" rel="external">"Mechanisms of action of selective estrogen receptor modulators and down-regulators", section on 'ESR1 gene mutations'</a>.)</p><p>The predictive value of ER is clearly demonstrated by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) meta-analysis of randomized trials of adjuvant <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> [<a href="#rid2">2</a>]. In patients with ER-positive disease, tamoxifen significantly reduced the risk of recurrence by 39 percent (rate ratio 0.61) and death by 30 percent (rate ratio 0.696) throughout 15 years of follow-up. The benefit was independent of PR status, age, nodal status, or use of adjuvant chemotherapy. By contrast, tamoxifen had no impact on relapse or survival rates among patients with ER-negative breast cancer.</p><p>Whether ovarian suppression with gonadotropin-releasing hormone (GnRH) agonists improves breast cancer outcomes for women with breast cancer is not entirely clear, though there is a more established role for its use in subsets of patients with high-risk, hormone receptor-positive rather than hormone receptor-negative disease [<a href="#rid13">13-17</a>] (see  <a class="medical medical_review" href="/z/d/html/120706.html" rel="external">"Adjuvant endocrine therapy for premenopausal women with hormone receptor-positive breast cancer", section on 'Ovarian suppression plus endocrine therapy'</a>). Any potential therapeutic role for GnRH agonists in hormone receptor-negative breast cancer requires further investigation.</p><p>In keeping with American Society of Clinical Oncology (ASCO) guidelines, ER/PR analysis should be performed routinely in all invasive breast cancers [<a href="#rid18">18</a>]. Unfortunately, reproducibility of immunohistochemistry measurements of ER is an issue, with reports of moderate interobserver and interlaboratory concordance for strongly positive tumors, but lower concordance for weakly ER-positive tumors [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/747.html" rel="external">"Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy"</a> and  <a class="medical medical_review" href="/z/d/html/749.html" rel="external">"Adjuvant endocrine and targeted therapy for postmenopausal women with hormone receptor-positive breast cancer"</a> and  <a class="medical medical_review" href="/z/d/html/778.html" rel="external">"Treatment for hormone receptor-positive, HER2-negative advanced breast cancer"</a>.) </p><p class="headingAnchor" id="H1585725638"><span class="h2">HER2 predicting response to HER2-directed therapy</span><span class="headingEndMark"> — </span>Following the introduction of <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">trastuzumab</a>, human epidermal growth factor receptor 2 (HER2) is mainly used as a predictive factor, identifying those patients who might benefit from treatments that target HER2, both in the adjuvant and metastatic disease settings. The predictive value of HER2 is evident in all major adjuvant [<a href="#rid20">20-22</a>] and metastatic [<a href="#rid23">23-25</a>] trials of HER2-directed therapies.</p><p>Guidelines for HER2 testing from a joint ASCO/College of American Pathologists (CAP) consensus panel [<a href="#rid26">26</a>], the data on HER2 status, and treatment of HER2-positive breast cancer are covered separately. (See  <a class="medical medical_review" href="/z/d/html/780.html" rel="external">"HER2 and predicting response to therapy in breast cancer", section on 'Testing for HER2 expression'</a> and  <a class="medical medical_review" href="/z/d/html/773.html" rel="external">"Adjuvant systemic therapy for HER2-positive breast cancer"</a> and  <a class="medical medical_review" href="/z/d/html/15749.html" rel="external">"Systemic treatment for HER2-positive metastatic breast cancer"</a>.)</p><p>Although HER2 overexpression is an established tool for determining response to HER2-directed therapies, some evidence suggests its limitations. For example, the intrinsic subtype may identify HER2-positive tumors that are less likely to respond to HER2-directed therapy. In a study of almost 1400 tumor samples from patients with clinically identified HER2-positive disease (either by immunohistochemistry or fluorescent in situ hybridization), those with basal-like intrinsic subtype did not experience improved recurrence-free survival with the addition of <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">trastuzumab</a> (hazard ratio 1.06, 95% CI 0.53-2.13) [<a href="#rid27">27</a>]. Although intrinsic subtype cannot replace conventional histopathologic evaluation of HER2 status, it may identify a subset of HER2-positive, basal-like cancers for which alternative treatment strategies may be appropriate.</p><p class="headingAnchor" id="H2164504509"><span class="h2">Gene expression profiles in predicting response to chemotherapy in hormone receptor-positive/HER2 negative cancers</span><span class="headingEndMark"> — </span>The decision of whether to recommend adjuvant chemotherapy should be based on anatomic prognoses (nodal status, tumor size) and biology of the tumor. Patients with ER-, PR-, and HER2-negative cancers should in general receive adjuvant chemotherapy, especially if they have positive lymph nodes or tumors &gt;1 cm.</p><p>The National Comprehensive Cancer Network notes that although several <strong>prognostic</strong> assays are available to estimate recurrence risk (eg, Oncotype DX RS, EndoPredict, Predictor Analysis of Microarray 50 [PAM50], the Breast Cancer Index, and the Amsterdam 70-gene profile [MammaPrint]), only the RS has been validated for <strong>predicting</strong> the benefit of adding adjuvant chemotherapy to further reduce the risk of recurrence [<a href="#rid28">28</a>].</p><p>The use of gene expression profiles in deciding whether to use chemotherapy in hormone receptor-positive, HER2-negative disease is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/126631.html" rel="external">"Deciding when to use adjuvant chemotherapy for hormone receptor-positive, HER2-negative breast cancer", section on 'Node-negative disease'</a>.)</p><p class="headingAnchor" id="H3151007179"><span class="h2">Tumor infiltrating lymphocytes</span><span class="headingEndMark"> — </span>Observational analyses have demonstrated a correlation between the extent of lymphocytic infiltration in the tumor or surrounding stroma, referred to as tumor-infiltrating lymphocytes (TILs), and the likelihood of achieving a pathologic complete response with neoadjuvant chemotherapy (NACT), particularly in HER2-negative and triple negative breast cancers [<a href="#rid29">29</a>]. This is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/106774.html" rel="external">"Neoadjuvant therapy for patients with HER2-positive breast cancer", section on 'Tumor prognostic features'</a>.)</p><p class="headingAnchor" id="H3929974683"><span class="h1">PROGNOSTIC FACTORS IN ROUTINE CLINICAL USE</span></p><p class="headingAnchor" id="H2210594379"><span class="h2">Approach to use of prognostic markers</span><span class="headingEndMark"> — </span>For women with newly diagnosed, non-metastatic breast cancer, we routinely utilize the following clinical factors to help determine prognosis:</p><p class="bulletIndent1"><span class="glyph">●</span>Age and race (see <a class="local">'Patient features'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pathologic factors, including tumor stage (see <a class="local">'Pathologic factors'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tissue markers, including hormone receptor expression and/or human epidermal growth factor receptor 2 (HER2) overexpression (see <a class="local">'Receptor status'</a> below and <a class="local">'ER predicting response to endocrine therapy'</a> above and <a class="local">'HER2 predicting response to HER2-directed therapy'</a> above)</p><p></p><p>Beyond clinical factors, gene expression profiling is increasingly utilized in selected patients. Assays that are in clinical use, as well as those that are under investigation, are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/126631.html" rel="external">"Deciding when to use adjuvant chemotherapy for hormone receptor-positive, HER2-negative breast cancer", section on 'Node-negative disease'</a>.)</p><p>There is overlap between prognostic markers, but some still retain independent variables (eg, estrogen receptor [ER], grade, Oncotype DX Recurrence Score [RS], Ki-67).</p><p class="headingAnchor" id="H2258864872"><span class="h2">Patient features</span><span class="headingEndMark"> — </span>Both younger and older age at diagnosis have been associated with a worse prognosis [<a href="#rid30">30</a>]. However, contemporary studies suggest that recurrences among young women diagnosed with breast cancer have become less frequent over time [<a href="#rid31">31</a>].</p><p>Differences exist on the impact of age among breast cancer subtypes. For example, for patients with HER2-positive breast cancer, age is not associated with early relapse or survival, with or without <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">trastuzumab</a> treatment [<a href="#rid32">32</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age</strong> – Overall, age alone should not be a factor in whether a patient should or should not receive specific types of local or systemic therapies.</p><p></p><p class="bulletIndent1">The impact of age on prognosis is demonstrated in the following studies:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients age &lt;35 years have a worse overall survival (OS) and recurrence-free survival [<a href="#rid33">33</a>]. For example, in one study five-year survival rates for women &lt;35 years were 75 percent, versus 84 to 88 percent in women 35 to 69 years [<a href="#rid34">34</a>]. These patients generally present with a later stage, have ER-negative disease in a higher proportion, and receive more aggressive treatment. However, even after adjustment for stage, tumor characteristics (grade, ER status), and treatment, patients in this age group experience a relative increase in breast cancer mortality of at least 70 percent [<a href="#rid34">34</a>], indicating a more aggressive tumor biology in these patients [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age may be of greater prognostic significance in patients with luminal cancers than in other types of breast cancer. In a study of approximately 17,500 women with stage I to III breast cancer, women ≤40 years of age at diagnosis had increased breast cancer mortality relative to older patients (hazard ratio [HR] 1.4, 95% CI 1.2-1.7), with the most significant increases observed in patients with luminal A and B cancers, and no differences seen in patients with HER2 subtypes [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Several population-based studies and randomized trials demonstrate increased breast cancer mortality in older adult patients (&gt;65 years) [<a href="#rid37">37-39</a>]. This is attributed to a later stage at diagnosis, higher comorbidity, and treatment discrepancies [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/761.html" rel="external">"Treatment of metastatic breast cancer in older women"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Menopausal status</strong> – Among premenopausal patients who received adjuvant chemotherapy, chemotherapy-induced amenorrhea and lack of resumption of menstrual cycles after chemotherapy is associated with improved survival, after controlling for standard prognostic variables, particularly for hormone receptor-positive disease [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Race</strong> – Racial disparities in breast cancer outcomes may be due in part to socioeconomic reasons [<a href="#rid41">41</a>], but may also relate to a more aggressive tumor biology among African Americans. However, there is no evidence that African American women should receive different chemotherapy regimens than women of other races with the same biologic subset of breast cancer.</p><p></p><p class="bulletIndent1">In a retrospective cohort study with over 23,000 participants with triple-negative breast cancer, African American patients had lower odds of receiving surgery (odds ratio [OR], 0.69) and chemotherapy (OR, 0.89) after adjustment for sociodemographic, clinicopathologic, and county-level factors [<a href="#rid42">42</a>]. The HR of breast cancer mortality was 1.28 for African American individuals after adjustment for sociodemographic factors.</p><p></p><p class="bulletIndent1">Studies have also suggested more aggressive biology in tumors occurring in African American patients. In a retrospective study of 280,000 women with non-metastatic breast cancer showed that although African American women were more likely to receive neoadjuvant chemotherapy than White women, they were less likely to experience a pathologic complete response (pCR) for triple-negative and HER2-positive breast cancers [<a href="#rid43">43</a>]. Evidence also suggests that African American women are more often diagnosed with the biologically aggressive basal-like subtype of breast cancer [<a href="#rid44">44,45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Smoking</strong> – Cigarette smoking, both before and after breast cancer diagnosis, has been linked to increased breast cancer mortality. In a study including almost 21,000 women diagnosed with non-metastatic breast cancer, during a median follow-up of 12 years, approximately 2900 patients died of breast cancer [<a href="#rid46">46</a>]. Patients who smoked actively during the year prior to their breast cancer diagnosis were more likely than never-smokers to die of breast cancer (HR 1.25, 95% CI 1.13-1.37). Furthermore, the 10 percent of women who continued to smoke after diagnosis were more likely than never-smokers to die of breast cancer (HR 1.72, 95% CI 1.13-2.60). When compared with women who continued to smoke after diagnosis, those who quit smoking had lower breast cancer mortality (HR 0.67, 95% CI 0.38-1.19), suggesting that among women who smoke, smoking cessation may improve outcomes after a diagnosis of breast cancer.</p><p></p><p class="headingAnchor" id="H103668750"><span class="h2">Mammographic features</span><span class="headingEndMark"> — </span>Screen-detected breast cancers have a better prognosis than those identified by clinical exam [<a href="#rid47">47-49</a>]. This is generally due to the stage of disease at diagnosis, with those tumors detected by screening more likely to be smaller and not involving the regional nodes.</p><p>Although breast density on mammogram is a well-recognized risk factor for breast cancer, it is not prognostic for women diagnosed with breast cancer [<a href="#rid50">50</a>]. (See <a class="local">'Tumor stage'</a> below.)</p><p>Whether multifocal (ie, invasive tumors identified within the same breast quadrant) or multicentric (ie, invasive tumors identified in separate breast quadrants) tumors influence prognosis is controversial. While some evidence suggests they are associated with a poor prognosis [<a href="#rid51">51</a>], other data suggest that multifocality does not influence prognosis [<a href="#rid52">52</a>]. Regardless of method of detection (eg, by mammogram, ultrasound, or magnetic resonance imaging), findings of multifocality or multicentricity should not by themselves be included in the decision regarding adjuvant therapy for patients with newly diagnosed, non-metastatic breast cancer.</p><p class="headingAnchor" id="H682639978"><span class="h2">Pathologic factors</span></p><p class="headingAnchor" id="H103673173"><span class="h3">Tumor stage</span><span class="headingEndMark"> — </span>In general, stage is a prognostic factor. Breast cancer is staged according to tumor size, whether and how many nodes are involved, and whether metastatic disease is present (Tumor, Node, Metastasis [TNM] system ( (<a class="graphic graphic_table graphicRef110848" href="/z/d/graphic/110848.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef110851" href="/z/d/graphic/110851.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef117141" href="/z/d/graphic/117141.html" rel="external">table 3</a>)).</p><p>In validation cohorts of the American Joint Committee on Cancer (AJCC) eighth edition staging system, the five-year disease-free survival (DFS) rates, according to anatomic stage, were as follows: for stage I disease, 98 to 100 percent; for stage II disease, 85 to 98 percent; and for stage III disease, approximately 70 to 95 percent [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/z/d/html/800.html" rel="external">"Tumor, node, metastasis (TNM) staging classification for breast cancer"</a>.)</p><p class="headingAnchor" id="H682639999"><span class="h4">Tumor size</span><span class="headingEndMark"> — </span>Tumor size (T), defined as the largest diameter of the primary breast tumor, was recognized early as an important prognostic factor in breast cancer [<a href="#rid54">54-56</a>].</p><p>Tumor size is correlated with nodal involvement, but the prognostic value of the two factors is independent. In a meta-analysis of 88 trials involving over 62,000 patients with ER-positive breast cancer who were disease-free after five years of scheduled endocrine therapy, the risk of distant recurrence was correlated with the original tumor size over years 5 to 20 [<a href="#rid57">57</a>]. Among those with no involved lymph nodes, the risk of distant recurrence for T1 versus T2 tumors was 13 versus 19 percent, respectively. Among those with one to three involved nodes, the risks among those with T1 versus T2 tumors were 20 versus 26 percent; and among those with four to nine involved nodes, the risks for T1 and T2 tumors were 34 versus 41 percent, respectively. In triple-negative tumors, the correlation of tumor size with nodal status and with prognosis is much weaker [<a href="#rid58">58</a>]. (See <a class="local">'Nodal involvement'</a> below.)</p><p>The impact of multifocal (ie, invasive tumors identified within the same breast quadrant) or multicentric (ie, invasive tumors identified in separate breast quadrants) tumors on prognosis is controversial, with some evidence that they are associated with a poor prognosis [<a href="#rid51">51</a>] and other data suggesting they do not impact prognosis [<a href="#rid52">52</a>]. The eighth edition TNM staging system does not assign independent value to multifocality or multicentricity and uses the diameter of the largest lesion to assign T stage [<a href="#rid53">53</a>].</p><p>Inflammatory breast cancer (IBC, T4d) is a rare but highly aggressive form of breast cancer characterized by a clinical picture of inflammation in the breast and a poor prognosis. The hallmark of diagnosis is made by skin biopsy demonstrating dermal lymphatic invasion. IBC should not be confused with the histologic presence of inflammation or inflammatory cells in a breast cancer, which is considered a good prognostic feature. (See  <a class="medical medical_review" href="/z/d/html/768.html" rel="external">"Inflammatory breast cancer: Clinical features and treatment"</a> and <a class="local">'Pathologic factors'</a> above.)</p><p class="headingAnchor" id="H682640006"><span class="h4">Nodal involvement</span><span class="headingEndMark"> — </span>Nodal involvement (ie, the number of ipsilateral axillary nodes with metastatic tumor growth) is a strong and independent negative prognostic factor. </p><p>Among women with no evidence of metastatic disease (M0), the five-year survival rate for those who present with localized (ie, breast only) versus regional disease (ie, pathologic node involvement) is 99 and 85 percent, respectively [<a href="#rid59">59</a>]. Even small tumors (&lt;2 cm) have a worse prognosis in the presence of pathologic node involvement. In the meta-analysis discussed above including over 62,000 patients with ER-positive breast cancer who were recurrence free after five years of endocrine therapy, the risk of distant recurrence over years 5 to 20 for those with T1 tumors was 13 percent in the absence of lymph node involvement, 20 percent among those with one to three involved lymph nodes, and 34 percent among those with four to nine involved nodes [<a href="#rid57">57</a>].</p><p>While lymph node macrometastasis is a well-established independent prognostic factor, the significance of metastatic disease &lt;2 mm (micrometastases, pN1<sub>mic</sub>) or isolated tumor cells (ITC, pN0<sub>ITC</sub>) in axillary nodes is less clear. However, the evidence suggests that patients with pN1<sub>mic</sub> breast cancer have a worse outcome compared with those with node-negative breast cancer while the presence of isolated tumor cells does not influence prognosis. This is demonstrated in the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective cohort study of 3369 patients with breast cancer, patients with pN1<sub>mic</sub> disease (n = 123) had a significantly lower breast cancer-specific five-year survival compared with N0 patients (80 versus 87 percent) [<a href="#rid60">60</a>]. However, there was no difference in survival among patients with pN0<sub>ITC</sub> and N0 disease. In addition, the presence of pN1<sub>mic</sub> and not pN0<sub>ITC</sub> was associated with a trend towards a worse OS compared with patients with pN0 breast cancer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The prognostic impact of micrometastatic nodal involvement was shown in a large meta-analysis of 58 studies [<a href="#rid61">61</a>]. Patients with microscopic pathologic node involvement were at an increased risk of death compared with patients with pN0 disease (pooled HR of death 1.44, 95% CI 1.29-1.62). In addition, this study also suggested there was a negative prognostic impact of occult metastases on survival when identified by the retrospective examination of what were initially determined to be negative sentinel nodes (pooled HR for mortality 1.45, 95% CI 1.11-1.88).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 trial, occult metastasis was an independent prognostic factor for relapse; however, it had no meaningful effect on OS (94.6 versus 95.8 percent) [<a href="#rid62">62</a>].</p><p></p><p class="headingAnchor" id="H27535500"><span class="h4">Metastatic disease</span><span class="headingEndMark"> — </span>The presence of metastatic disease is a poor prognostic factor. Women with newly diagnosed breast cancer and evidence of metastatic disease, regardless of whether it was detected clinically or radiographically, should be treated as having metastatic breast cancer. The prognostic factors and the approach to patients with metastatic disease are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/88415.html" rel="external">"Prognostic and predictive factors in metastatic breast cancer"</a> and  <a class="medical medical_review" href="/z/d/html/767.html" rel="external">"Overview of the approach to metastatic breast cancer"</a> and  <a class="medical medical_review" href="/z/d/html/760.html" rel="external">"The role of local therapies in metastatic breast cancer"</a>.) </p><p class="headingAnchor" id="H103673130"><span class="h3">Tumor morphology</span><span class="headingEndMark"> — </span>The most common type is invasive ductal carcinoma (IDC), accounting for greater than 70 percent of all cases, followed by invasive lobular carcinoma (ILC), with a frequency of about 10 percent [<a href="#rid63">63</a>]. ILC has a distinctive biology and clinical behavior compared with IDC, although the prognostic impact of histology appears to vary with time. This was shown in a pooled analysis of over 9000 patients with extended follow-up that reported a 16 percent lower risk of recurrence for ILC compared with IDC during the first six years of follow-up; however, ILC conferred a 54 percent higher risk of relapse after six years [<a href="#rid64">64</a>].</p><p>Other subtypes of invasive breast cancer have been described. Tubular, papillary, mucinous, medullary, and adenoid cystic carcinoma have been associated with a good prognosis; by contrast, micropapillary and metaplastic carcinomas appear to confer a worse prognosis. (See  <a class="medical medical_review" href="/z/d/html/783.html" rel="external">"Pathology of breast cancer"</a>.)</p><p class="headingAnchor" id="H682640012"><span class="h3">Histologic grade</span><span class="headingEndMark"> — </span>The grade of breast cancer is assigned using the Elston-Ellis grading system, which characterizes the degree of tumor differentiation by the percentage of tubule formation, nuclear pleomorphism, and mitotic activity [<a href="#rid65">65</a>]. (See  <a class="medical medical_review" href="/z/d/html/783.html" rel="external">"Pathology of breast cancer"</a>.)</p><p>In the original report, this system was found to be prognostic [<a href="#rid65">65</a>], and this has been independently confirmed by others [<a href="#rid66">66</a>]. For example, in a study including over 2200 operable breast cancer cases, there was a correlation between histologic grade and worsened outcomes, with an HR for worsened breast cancer-specific survival (BCSS) of 1.6 for grade 2 versus 1 cancers (95% CI 1.1-2.5) and 3.9 for grade 3 versus grade 1 cancers (95% CI 2.6-5.8) [<a href="#rid66">66</a>]. The correlation persisted after multivariate adjustment for other prognostic indications, including lymph node involvement, tumor size, and vascular invasion.</p><p class="headingAnchor" id="H682640019"><span class="h3">Peritumoral lymphovascular invasion</span><span class="headingEndMark"> — </span>The presence of lymphovascular invasion appears to be a poor prognostic indicator, particularly in higher-grade tumors. This was shown in a cohort study of 1704 patients that did not receive any systemic adjuvant therapy, in which peritumoral lymphovascular invasion (PLVI) was an independent risk factor for local recurrence and death [<a href="#rid67">67</a>].</p><p>However, more contemporary reports are less clear about whether PLVI is of independent prognostic value [<a href="#rid68">68,69</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a population-based study of more than 15,000 patients, PLVI was significantly associated with other adverse prognostic factors (tumor size, grade, positive nodal status, ductal histology, ER negativity). In the absence of these other factors, PLVI had no effect on survival. At five years, 98 percent of patients without PLVI were alive (versus 94.1 percent for the patients with PLVI) [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another retrospective analysis of 2754 patients treated in two adjuvant therapy trials, PLVI was associated with worse DFS, but its prognostic value was abrogated by adjuvant endocrine therapy [<a href="#rid69">69</a>].</p><p></p><p>Taken together, these studies indicate that PLVI has a prognostic value, but its clinical utility remains to be determined.</p><p class="headingAnchor" id="H3111847637"><span class="h3">Ki-67</span><span class="headingEndMark"> — </span>The relationship between Ki-67 status and prognosis in early breast cancer has been extensively studied [<a href="#rid70">70</a>]. Despite heterogeneity in clinical trials and Ki-67 assessment methods used, the results of two large meta-analyses are consistent with the independent prognostic value of Ki-67 [<a href="#rid71">71,72</a>]. According to an international working group, Ki-67 has clinical validity but concluded that clinical utility is evident only for prognosis estimation in anatomically favorable estrogen receptor-positive/HER2-negative cancers to identify those who do not need adjuvant chemotherapy [<a href="#rid73">73</a>]. In this T1-2, N0-1 patient group, the consensus was that Ki-67 ≤5, or ≥30 percent, can be used to estimate prognosis. Ki-67 can also be considered in the selection of patients with high-risk hormone receptor-positive, HER2-negative breast cancer for adjuvant <a class="drug drug_general" data-topicid="115098" href="/z/d/drug information/115098.html" rel="external">abemaciclib</a>, as discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/749.html" rel="external">"Adjuvant endocrine and targeted therapy for postmenopausal women with hormone receptor-positive breast cancer", section on 'CDK 4/6 inhibitors for select patients with high-risk disease'</a>.)</p><p>As an example of available data, one meta-analysis that included 46 studies (and over 12,000 patients) reported that high Ki-67 levels were associated with [<a href="#rid71">71</a>]:</p><p class="bulletIndent2"><span class="glyph">•</span>A higher risk of relapse in both node-positive (HR 1.59, 95% CI 1.35-1.87) and node-negative disease (HR 2.31, 95% CI 1.83-2.92).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Worse breast cancer survival in node-positive (HR for death 2.33, 95% CI 1.83-2.95) and node-negative disease (HR 2.54, 95% CI 1.65-3.91).</p><p></p><p>An analysis of samples from randomized controlled trials with central determination of Ki-67 confirmed the independent prognostic value of Ki-67 (multivariate HR 1.05-1.72 for relapse) [<a href="#rid70">70</a>].</p><p class="headingAnchor" id="H682640025"><span class="h3">Receptor status</span></p><p class="headingAnchor" id="H682640032"><span class="h4">Hormone receptors</span><span class="headingEndMark"> — </span>ER and PR expression are generally associated with improved breast cancer outcomes, at least over the short term. ER should be used to determine if a patient should or should not receive adjuvant endocrine therapy. (See <a class="local">'ER predicting response to endocrine therapy'</a> above.)</p><p>Data suggest that OS, DFS, and time to treatment failure are all positively related to ER and PR levels [<a href="#rid74">74-76</a>]. However, while the annual rate of recurrence for ER-positive cancers is lower in the first five years after initial treatment compared with ER-negative cancers, studies suggest it may be higher with longer-term follow-up [<a href="#rid77">77,78</a>]. For example, in a study of over 4000 patients with operable breast cancer enrolled in International Breast Cancer Study Group clinical trials I to V, patients with ER-positive disease had a lower annual risk of recurrence during the first five years after their initial treatment compared with those with ER-negative disease (9.9 versus 11.5 percent). However, after five years, patients with ER-positive disease had a higher annual risk of recurrence (5 to 10 years: 5.4 versus 3.3 percent; 10 to 15 years: 2.9 versus 1.3 percent; 15 to 20 years: 2.8 versus 1.2 percent) [<a href="#rid78">78</a>]. Other data have shown the breast cancer recurrences in women with early-stage, ER-positive breast cancers continue to occur steadily after five years of endocrine therapy to at least 20 years, with the risk of distant recurrences being strongly correlated with the original cancer stage [<a href="#rid57">57</a>]. The long-term recurrence risk of ER-positive cancers has given rise to interest in extended endocrine therapy courses. (See  <a class="medical medical_review" href="/z/d/html/749.html" rel="external">"Adjuvant endocrine and targeted therapy for postmenopausal women with hormone receptor-positive breast cancer", section on 'Duration of endocrine treatment'</a>.)</p><p>ER status is also associated with specific site(s) of metastatic spread. For unclear reasons, ER-positive tumors are more likely to develop clinically apparent metastases in bone, soft tissue, or the reproductive/genital tracts; by contrast, ER-negative tumors more commonly metastasize to brain and liver, sites that are associated with shorter survival [<a href="#rid79">79</a>].</p><p>ER-positive tumors are more likely to be histologically well-differentiated [<a href="#rid80">80-82</a>], to have a lower fraction of dividing cells, and to be diploid [<a href="#rid83">83</a>]. They are also less likely to be associated with mutations, loss, or amplification of breast cancer-related genes such as <em>p53</em> [<a href="#rid84">84,85</a>], <em>HER2</em> [<a href="#rid86">86-88</a>], or <em>HER1</em> (the epidermal growth factor receptor [<em>EGFR</em>]) [<a href="#rid89">89,90</a>], all of which have been associated with a poorer prognosis. (See  <a class="medical medical_review" href="/z/d/html/780.html" rel="external">"HER2 and predicting response to therapy in breast cancer", section on 'HER2 status and predicting treatment response'</a>.)</p><p>PR appears to be prognostic and independent of ER [<a href="#rid91">91,92</a>]. This was shown in a large population-based cohort study that included over 1000 women with early breast cancer, all of whom underwent primary surgery with curative intent [<a href="#rid92">92</a>]. Absent PR expression was associated with poorer prognosis for OS, BCSS, and DFS, even within the ER-positive, lymph node-negative group (HR for BCSS 3.17, 95% CI 1.43-7.01), and was not influenced by endocrine therapy. These data are supported by the finding that patients with ER-positive, PR-negative disease have a more aggressive subtype of hormone receptor-positive breast cancer [<a href="#rid92">92</a>], and often fall into the luminal B subtype of tumors [<a href="#rid93">93</a>].</p><p>In general, tumors that are singly hormone receptor positive (ie, ER positive and PR negative, or PR positive and ER negative) appear to have a worse prognosis than those that are ER positive and PR positive. [<a href="#rid94">94</a>].</p><p class="headingAnchor" id="H682640038"><span class="h4">HER2 overexpression</span><span class="headingEndMark"> — </span>Assay for human epidermal growth factor receptor 2 (HER2) overexpression and/or amplification is a routine part of the diagnostic work-up on all primary breast cancers [<a href="#rid18">18,26</a>]. HER2 overexpression contends an unfavorable prognosis, particularly if patients are not treated with chemotherapy and HER2-directed agents. However, the added value of this information in clinical practice is questionable because outcomes are heavily influenced by the administration of therapy [<a href="#rid18">18</a>]. In women with breast cancer, the main benefit of HER2 testing is its predictive value for appropriate candidates who should receive HER2-directed agents. (See  <a class="medical medical_review" href="/z/d/html/780.html" rel="external">"HER2 and predicting response to therapy in breast cancer"</a> and <a class="local">'Predictive factors'</a> above.)</p><p>In the absence of systemic therapy, HER2 overexpression is a marker of poor prognosis in patients with pathologically node-positive [<a href="#rid87">87,95</a>] and node-negative breast cancer [<a href="#rid96">96</a>]. In addition, data suggest that HER2 retains prognostic value even in the presence of small tumors ≤1 cm.</p><p class="headingAnchor" id="H2721771884"><span class="h3">Tumor infiltrating lymphocytes</span><span class="headingEndMark"> — </span>Tumor-infiltrating lymphocytes (TILs) have been shown to be an adverse prognostic factor for survival in luminal-HER2-negative breast cancer [<a href="#rid29">29</a>]. Guidelines for standardized assessment of TILs have been published [<a href="#rid97">97</a>].</p><p class="headingAnchor" id="H2931768232"><span class="h2">Gene expression-based and clinical prognostic profiles</span><span class="headingEndMark"> — </span>The emergence of genomics (which evaluate DNA) and transcriptomics (which evaluate RNA) techniques and the ability to simultaneously measure the expression of thousands of genes has led to the identification of biology-based prognostic profiles, several of which have been validated and are in clinical use, for example the Oncotype Dx Recurrence Score (RS). While prognostic contributions of specific genes in the RS (or their combinations) are unknown, the panel overall is better at prognostication than clinicopathologic features such as grade or Ki-67. The RS and other gene-expression based profiles are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/126631.html" rel="external">"Deciding when to use adjuvant chemotherapy for hormone receptor-positive, HER2-negative breast cancer"</a>.)</p><p>The field is under development with intensive research efforts ongoing, aiming to define the clinical utility and the indications for each of the prognostic profiles in routine practice [<a href="#rid11">11</a>]. Furthermore, a next generation of molecular profiles should be anticipated with the implementation of advances in large-scale sequencing of tumor genomes [<a href="#rid98">98-103</a>]. (See <a class="local">'Global genomic profiling'</a> below.)</p><p>Additionally, clinical risk prediction calculators exist that allow the user to input patient and tumor characteristics and garner prognostic information. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>The ESTIMATE online tool was derived from a registry of over 264,000 women with invasive, non-metastatic breast cancer, and estimates the residual cumulative risk of breast cancer specific mortality (BCSM) and non-BCSM to year 20, after any specified time from initial diagnosis [<a href="#rid104">104,105</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The CTS5 categorizes patients who have been disease free for five years into low, intermediate, and high risk and estimates an absolute risk for developing distant recurrences between 5 and 10 years [<a href="#rid106">106</a>], although one study notes that it overestimates the risk in high-risk patients [<a href="#rid107">107</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The UK <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fbreast.predict.nhs.uk%2F&amp;token=ktJxJWFyo6TX%2B3OPT%2FtieVv8LEH1afMscAzXSqUKz184T3jx7l4QDZ%2FUJBISMxSW&amp;TOPIC_ID=782" target="_blank">PREDICT</a> tool estimates risks of recurrence based on clinical features and predicts benefit of therapy, as discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/126631.html" rel="external">"Deciding when to use adjuvant chemotherapy for hormone receptor-positive, HER2-negative breast cancer", section on 'Clinical features that guide the use of chemotherapy'</a>.)</p><p></p><p class="headingAnchor" id="H1529296388"><span class="h1">OTHER PROGNOSTIC FACTORS</span></p><p class="headingAnchor" id="H697669959"><span class="h2">Global genomic profiling</span><span class="headingEndMark"> — </span>The cellular and molecular heterogeneity of breast cancer and the large number of genes involved in controlling cell growth, death, and differentiation emphasize the importance of studying multiple genetic alterations in concert. Global gene expression profiling allows the simultaneous measurement of the activity (expression) of thousands of genes in a breast cancer cell, but is not routinely applied in clinical care. Future applications of high-throughput examinations will doubtless take the same approach to proteins (proteomics), genome-wide germline variability (single-nucleotide polymorphisms), or cellular metabolism (metabolomics).</p><p>Gene expression studies have identified several distinct breast cancer subtypes that differ markedly in prognosis and in the therapeutic targets they express [<a href="#rid103">103,108-115</a>]. The list of genes that differentiates these subtypes is called the intrinsic list and is made up of several clusters of genes relating to estrogen receptor (ER) expression (the luminal cluster), human epidermal growth factor receptor 2 (HER2) expression, and a unique cluster of genes called the basal cluster. Others are being identified as investigators continue to study the genomic data derived from breast cancer specimens.</p><p>The intrinsic subtypes segregate into two groups that correspond to expression of hormone receptor-related genes. This segregation is consistent with both the literature and clinical experience that show ER-positive and ER-negative cancers define biologically distinct phenotypes that may derive from different progenitor cells [<a href="#rid112">112</a>]. However, the analytical validity and clinical utility of determining the intrinsic subtypes depend on the specific assay and the precise clinical use in which the assay will be applied. The Predictor Analysis of Microarray 50 (PAM50) assesses intrinsic subtype [<a href="#rid116">116</a>]. (See  <a class="medical medical_review" href="/z/d/html/126631.html" rel="external">"Deciding when to use adjuvant chemotherapy for hormone receptor-positive, HER2-negative breast cancer", section on 'PAM50 risk of recurrence score'</a>.)</p><p>A brief review of the genomic profiles in breast cancer is covered below.</p><p class="headingAnchor" id="H697669998"><span class="h3">Luminal subtypes</span><span class="headingEndMark"> — </span>Luminal A- and luminal B-expressed genes are associated with luminal epithelial cells of normal breast tissue and overlap with ER-positive breast cancers defined by clinical assays.</p><p>The name "luminal" derives from similarity in gene expression between these tumors and the luminal epithelium of the breast; they typically express luminal cytokeratins 8 and 18. These are the most common subtypes, make up the majority of ER-positive breast cancer, and are characterized by expression of ER, progesterone receptor (PR), and other genes associated with ER activation. Despite comprising the majority of ER-positive breast cancers, the luminal A and luminal B subtypes have some important molecular and prognostic distinctions.</p><p class="bulletIndent1"><span class="glyph">●</span>Luminal A tumors, which probably make up about 40 percent of all breast cancers, usually have high expression of ER-related genes, low expression of the HER2 cluster of genes, and low expression of proliferation-related genes [<a href="#rid117">117,118</a>]. Luminal A tumors are the most common subtype and, in general, carry the best prognosis of all breast cancer subtypes [<a href="#rid112">112-114,119-121</a>]. Despite this, most breast cancer deaths are from ER-positive, HER2-negative disease, and racial disparity in outcome is particularly found in this subset [<a href="#rid122">122</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The less common (approximately 20 percent) luminal B tumors have relatively lower (although still present) expression of ER-related genes, variable expression of the HER2 cluster, and higher expression of the proliferation cluster. Luminal B tumors carry a worse prognosis than luminal A tumors [<a href="#rid120">120</a>]. Most luminal B cancers have high recurrence scores as assessed by the 21-gene recurrence score assay and poor 70-gene prognostic signatures [<a href="#rid117">117</a>].</p><p></p><p class="headingAnchor" id="H697670004"><span class="h3">HER2-enriched</span><span class="headingEndMark"> — </span>The human epidermal growth factor receptor 2 (HER2)-enriched subtype (previously the HER2-positive/ER-negative subtype) makes up about 10 to 15 percent of breast cancers and is characterized by high expression of the HER2 and proliferation gene clusters and low expression of the luminal and basal clusters. For this reason, these tumors are most often negative for ER and PR, and positive for HER2.</p><p>However, the HER2-enriched subtype is not synonymous with clinically HER2-positive breast cancer. While clinical HER2-positive breast cancers are typically HER2 enriched, studies have shown that a large percentage of HER2-positive tumors are not HER2 enriched [<a href="#rid123">123-126</a>]. While the impact of HER2 targeting in these tumors is being studied, it is possible that at least some represent <em>HER2</em> mutations or other events in the HER2 signaling pathway producing a similar expression phenotype without <em>HER2</em> amplification or protein overexpression. Further discussion of the HER2-enriched subtype, and its utility as a predictive factor for neoadjuvant HER2-directed therapy, is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/106774.html" rel="external">"Neoadjuvant therapy for patients with HER2-positive breast cancer", section on 'Tumor prognostic features'</a>.) </p><p class="headingAnchor" id="H697670010"><span class="h3">ER-negative subtypes</span><span class="headingEndMark"> — </span>The estrogen receptor (ER)-negative genomic profile includes multiple subtypes, such as basal-like, claudin-low [<a href="#rid108">108</a>], interferon-rich [<a href="#rid127">127</a>], and mesenchymal and luminal androgen receptor subtypes [<a href="#rid128">128</a>], among others. Most of these fall under the category of triple-negative breast cancers because they are also PR negative and HER2 negative.</p><p>Of these, the best described is the claudin-low subtype. The basal-like subtype, so-called because of some similarity in gene expression to that of the basal epithelial cells of normal breast tissue, makes up about 15 to 20 percent of breast cancers. It is characterized by low expression of the luminal and HER2 gene clusters. For this reason, these tumors are typically ER negative, PR negative, and HER2 negative on clinical assays, which has prompted the nickname "triple-negative breast cancers" to describe them. However, while most triple-negative breast cancers are basal-like, and most basal-like tumors are triple-negative, there is significant discordance (up to 30 percent) between these two classification methods that must be kept in mind when evaluating studies focused upon basal-like breast cancer.</p><p>Triple-negative breast cancer is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/14227.html" rel="external">"ER/PR negative, HER2-negative (triple-negative) breast cancer"</a>.)</p><p class="headingAnchor" id="H103669152"><span class="h2">Markers of proliferation</span><span class="headingEndMark"> — </span>The proliferative rate of breast cancer appears to be prognostic. There are a variety of methods used to assess this, including mitotic counts, S-phase fractions as determined by flow cytometry, and immunohistochemistry using monoclonal antibodies to antigens found in proliferating cells. However, the most commonly studied method is to perform immunohistochemistry of the nuclear antigen Ki-67. (See <a class="local">'Ki-67'</a> above.)</p><p>Others are discussed in the sections below.</p><p class="headingAnchor" id="H682640050"><span class="h3">Urokinase plasminogen activator system</span><span class="headingEndMark"> — </span>Urokinase plasminogen activator (uPA) is a serine protease with an important role in cancer invasion and metastases [<a href="#rid129">129</a>]. When bound to its receptor (uPAR), uPA converts plasminogen into plasmin and mediates degradation of the extracellular matrix during tumor cell invasion. High levels of uPA and uPAR, as well as the plasminogen activator inhibitor PAI-1, have been associated with shorter survival in women with breast cancer [<a href="#rid130">130</a>]; by contrast, high levels of PAI-2 appear to be associated with better outcomes [<a href="#rid129">129,131-133</a>]. American Society of Clinical Oncology guidelines include the option for using uPA and PAI-1 to guide decisions on adjuvant systemic therapy for patients with node-negative, hormone receptor-positive, HER2-negative disease, but not for patients with HER2-positive or triple-negative disease [<a href="#rid134">134</a>].</p><p>A prospective trial involving almost 650 women with node-negative breast cancer was performed to evaluate the prognostic ability of cytosolic uPA and/or PAI-1 levels [<a href="#rid135">135,136</a>]. The results were then used to determine whether or not adjuvant chemotherapy was administered. At a median follow-up of 9.4 years, the following results were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Among women who were not treated with systemic chemotherapy (n = 409), the 10-year recurrence rate was significantly lower for those with low expression of both uPA and PAI-1 (13 versus 23 percent) [<a href="#rid136">136</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among women with high expression of either protein, adjuvant chemotherapy resulted in a lower risk of disease recurrence compared with observation only (21 versus 28 percent; hazard ratio 0.74, 95% CI 0.44-1.27) [<a href="#rid136">136</a>].</p><p></p><p>Despite these results, the enthusiasm for the use of uPA and PAI-1 as prognostic indicators in the United States is tempered by issues involving the assay methodology:</p><p class="bulletIndent1"><span class="glyph">●</span>The analysis requires a large volume of tissue obtained at the time of surgery rather than paraffin-embedded blocks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tissue must be frozen in order to proceed with enzyme-linked immunosorbent assay (ELISA), but the equipment and supplies to allow for freezing and storage are not generally available.</p><p></p><p>There are some data suggesting analysis can be performed on fresh tissue obtained at the time of core biopsy [<a href="#rid137">137</a>]. In addition, preliminary data suggest that immunohistochemistry staining for uPA and PAI-1 can be done using cryostat specimens [<a href="#rid138">138</a>]. However, further validation of these newer methods to analyze for both of these factors is required.</p><p class="headingAnchor" id="H103670323"><span class="h3">Other markers of invasion and metastasis</span><span class="headingEndMark"> — </span>Many other markers of invasion and metastatic potential have been proposed and/or studied in retrospective reports. For example, the prognostic role of p53 abnormalities in breast cancer has been evaluated. While the predictive value of somatic tumor protein p53 (<em>TP53</em>) is unclear, and we do not analyze tumors for this genetic alteration [<a href="#rid18">18</a>], data suggest that patients with germline mutations in <em>TP53</em> have a worse prognosis compared with other patients, independent of tumor size, node status, and hormone receptor status [<a href="#rid139">139-141</a>]. (See  <a class="medical medical_review" href="/z/d/html/785.html" rel="external">"Overview of hereditary breast and ovarian cancer syndromes", section on 'TP53 (Li-Fraumeni syndrome)'</a>.)</p><p>Others include measurement of the soluble extracellular domain of HER2 in serum, nm23, E-cadherin, the catenins, tissue inhibitors of metalloproteinases, prostate-specific antigen, tissue factor, and osteopontin [<a href="#rid142">142-151</a>]. Allelic loss, microsatellite instability, or methylation silencing of tumor suppressor genes may also provide prognostic information [<a href="#rid152">152-155</a>]. All of these potential indicators of prognosis require further evaluation and validation. None should be considered routine in the evaluation of breast cancer specimens.</p><p class="headingAnchor" id="H682640131"><span class="h2">Disseminated and circulating tumor cells</span><span class="headingEndMark"> — </span>Disseminated and/or circulating tumor cells (DTCs/CTCs) are likely to play an important role in the development of distant metastases in breast cancer. In contrast to clinically overt metastases, which represent a relatively late event in the natural history of solid tumors such as breast cancer, circulation of tumor cells in the bloodstream and/or their identification in bone marrow can be detected much earlier and are thought to be an early indicator of tumor spread [<a href="#rid156">156,157</a>]. While DTCs/CTCs both carry a poor prognosis [<a href="#rid158">158-169</a>], many patients with detectable DTCs/CTCs will not develop advanced breast cancer [<a href="#rid165">165-167,170,171</a>]. We do not routinely assess for DTCs/CTCs in the absence of high-quality data suggesting that this information improves outcomes in early breast cancer [<a href="#rid18">18,170,172-177</a>].</p><p>The investigative use of CTCs to predict benefit from adjuvant chemotherapy is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/126631.html" rel="external">"Deciding when to use adjuvant chemotherapy for hormone receptor-positive, HER2-negative breast cancer", section on 'Investigational assays'</a>.)</p><p class="headingAnchor" id="H3815662103"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113775.html" rel="external">"Society guideline links: Breast cancer"</a>.)</p><p class="headingAnchor" id="H103672604"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Terminology</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>By definition, a <strong>prognostic</strong> factor is capable of providing information on clinical outcome at the time of diagnosis, independent or in the absence of further therapy. By contrast, a <strong>predictive</strong> factor is capable of providing information on the likelihood of response to a given therapeutic modality. Although they can be separately classified, several factors in breast cancer are both prognostic and predictive (eg, the presence of overexpression of the human epidermal growth factor receptor 2 [HER2]). (See <a class="local">'Introduction'</a> above and <a class="local">'Definitions of predictive and prognostic factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Potential markers must demonstrate three factors to be of clinical use: analytical validity, clinical validity, and clinical utility. In addition, they should be able to provide significant and independent value; be determined feasibly, reproducible, and widely available; be readily interpretable; and must not consume tissue needed for other tests. (See <a class="local">'Definitions of predictive and prognostic factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Predictive factors</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All women with newly diagnosed, non-metastatic breast cancer should undergo tumor testing for hormone receptor expression and HER2 overexpression. In addition to being prognostic, this information can be used to tailor individualized plans for adjuvant therapy. (See <a class="local">'Receptor status'</a> above and <a class="local">'ER predicting response to endocrine therapy'</a> above and <a class="local">'HER2 predicting response to HER2-directed therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gene expression studies have identified several distinct breast cancer subtypes that differ markedly in prognosis. The major clusters are those relating to estrogen receptor expression (the luminal cluster), HER2 expression, and a unique cluster of genes called the basal cluster. Others are being identified as investigators continue to study the genomic data derived from breast cancer specimens.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognostic factors</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Both younger and older age at diagnosis is associated with a worse prognosis. In addition, African American women have a worse prognosis compared with White women, even after controlling for disease characteristics at presentation. (See <a class="local">'Patient features'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among pathologic factors, tumor stage (tumor size, nodal status, and whether or not metastatic disease is present) is the most important prognostic indicator. (See <a class="local">'Pathologic factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The enumeration of circulating tumor cells (CTCs) is prognostic for women with early, non-metastatic breast cancer. However, it is not clear how this information can be used to guide clinical care, and we do not routinely measure CTCs in this population. (See <a class="local">'Disseminated and circulating tumor cells'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R, Davies C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012; 379:432.</a></li><li><a class="nounderline abstract_t">Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378:771.</a></li><li><a class="nounderline abstract_t">Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011; 378:1707.</a></li><li><a class="nounderline abstract_t">Forouzanfar MH, Foreman KJ, Delossantos AM, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 2011; 378:1461.</a></li><li><a class="nounderline abstract_t">Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 1993; 85:1206.</a></li><li><a class="nounderline abstract_t">Hayes DF, Trock B, Harris AL. Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? Breast Cancer Res Treat 1998; 52:305.</a></li><li><a class="nounderline abstract_t">Febbo PG, Ladanyi M, Aldape KD, et al. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 2011; 9 Suppl 5:S1.</a></li><li><a class="nounderline abstract_t">Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 2009; 11:3.</a></li><li><a class="nounderline abstract_t">Moore HM, Kelly AB, Jewell SD, et al. Biospecimen reporting for improved study quality (BRISQ). J Proteome Res 2011; 10:3429.</a></li><li><a class="nounderline abstract_t">Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005; 23:2020.</a></li><li><a class="nounderline abstract_t">Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101:1446.</a></li><li><a class="nounderline abstract_t">NIH consensus conference. Treatment of early-stage breast cancer. JAMA 1991; 265:391.</a></li><li><a class="nounderline abstract_t">LHRH-agonists in Early Breast Cancer Overview group, Cuzick J, Ambroisine L, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007; 369:1711.</a></li><li><a class="nounderline abstract_t">Davidson NE, O'Neill AM, Vukov AM, et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 2005; 23:5973.</a></li><li><a class="nounderline abstract_t">Arriagada R, Lê MG, Spielmann M, et al. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol 2005; 16:389.</a></li><li><a class="nounderline abstract_t">International Breast Cancer Study Group (IBCSG), Castiglione-Gertsch M, O'Neill A, et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2003; 95:1833.</a></li><li><a class="nounderline abstract_t">Moore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015; 372:923.</a></li><li><a class="nounderline abstract_t">Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25:5287.</a></li><li><a class="nounderline abstract_t">Wells CA, Sloane JP, Coleman D, et al. Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union--an inter-laboratory study. Virchows Arch 2004; 445:119.</a></li><li><a class="nounderline abstract_t">Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659.</a></li><li><a class="nounderline abstract_t">Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673.</a></li><li><a class="nounderline abstract_t">Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365:1273.</a></li><li><a class="nounderline abstract_t">Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783.</a></li><li><a class="nounderline abstract_t">Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367:1783.</a></li><li><a class="nounderline abstract_t">Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366:109.</a></li><li><a class="nounderline abstract_t">Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25:118.</a></li><li><a class="nounderline abstract_t">Perez EA, Ballman KV, Mashadi-Hossein A, et al. Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial. J Natl Cancer Inst 2017; 109:1.</a></li><li><a class="nounderline abstract_t">Krop I, Ismaila N, Andre F, et al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. J Clin Oncol 2017; 35:2838.</a></li><li><a class="nounderline abstract_t">Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 2018; 19:40.</a></li><li><a class="nounderline abstract_t">Adami HO, Malker B, Holmberg L, et al. The relation between survival and age at diagnosis in breast cancer. N Engl J Med 1986; 315:559.</a></li><li><a class="nounderline abstract_t">Aalders KC, Postma EL, Strobbe LJ, et al. Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer. J Clin Oncol 2016; 34:2107.</a></li><li><a class="nounderline abstract_t">Partridge AH, Gelber S, Piccart-Gebhart MJ, et al. Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol 2013; 31:2692.</a></li><li><a class="nounderline abstract_t">Billena C, Wilgucki M, Flynn J, et al. 10-Year Breast Cancer Outcomes in Women ≤35 Years of Age. Int J Radiat Oncol Biol Phys 2021; 109:1007.</a></li><li><a class="nounderline abstract_t">Fredholm H, Eaker S, Frisell J, et al. Breast cancer in young women: poor survival despite intensive treatment. PLoS One 2009; 4:e7695.</a></li><li><a class="nounderline abstract_t">Anders CK, Hsu DS, Broadwater G, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 2008; 26:3324.</a></li><li><a class="nounderline abstract_t">Partridge AH, Hughes ME, Warner ET, et al. Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival. J Clin Oncol 2016; 34:3308.</a></li><li><a class="nounderline abstract_t">Bastiaannet E, Liefers GJ, de Craen AJ, et al. Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients. Breast Cancer Res Treat 2010; 124:801.</a></li><li><a class="nounderline abstract_t">Eaker S, Dickman PW, Bergkvist L, et al. Differences in management of older women influence breast cancer survival: results from a population-based database in Sweden. PLoS Med 2006; 3:e25.</a></li><li><a class="nounderline abstract_t">van de Water W, Markopoulos C, van de Velde CJ, et al. Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. JAMA 2012; 307:590.</a></li><li><a class="nounderline abstract_t">Swain SM, Jeong JH, Geyer CE Jr, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 2010; 362:2053.</a></li><li><a class="nounderline abstract_t">Silber JH, Rosenbaum PR, Clark AS, et al. Characteristics associated with differences in survival among black and white women with breast cancer. JAMA 2013; 310:389.</a></li><li><a class="nounderline abstract_t">Cho B, Han Y, Lian M, et al. Evaluation of Racial/Ethnic Differences in Treatment and Mortality Among Women With Triple-Negative Breast Cancer. JAMA Oncol 2021; 7:1016.</a></li><li><a class="nounderline abstract_t">Killelea BK, Yang VQ, Wang SY, et al. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base. J Clin Oncol 2015; 33:4267.</a></li><li><a class="nounderline abstract_t">Keenan T, Moy B, Mroz EA, et al. Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence. J Clin Oncol 2015; 33:3621.</a></li><li><a class="nounderline abstract_t">Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295:2492.</a></li><li><a class="nounderline abstract_t">Passarelli MN, Newcomb PA, Hampton JM, et al. Cigarette Smoking Before and After Breast Cancer Diagnosis: Mortality From Breast Cancer and Smoking-Related Diseases. J Clin Oncol 2016; 34:1315.</a></li><li><a class="nounderline abstract_t">Joensuu H, Lehtimäki T, Holli K, et al. Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 2004; 292:1064.</a></li><li><a class="nounderline abstract_t">Shen Y, Yang Y, Inoue LY, et al. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 2005; 97:1195.</a></li><li><a class="nounderline abstract_t">Wishart GC, Greenberg DC, Britton PD, et al. Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone? Br J Cancer 2008; 98:1741.</a></li><li><a class="nounderline abstract_t">Gierach GL, Ichikawa L, Kerlikowske K, et al. Relationship between mammographic density and breast cancer death in the Breast Cancer Surveillance Consortium. J Natl Cancer Inst 2012; 104:1218.</a></li><li><a class="nounderline abstract_t">Weissenbacher TM, Zschage M, Janni W, et al. Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified? Breast Cancer Res Treat 2010; 122:27.</a></li><li><a class="nounderline abstract_t">Lynch SP, Lei X, Chavez-MacGregor M, et al. Multifocality and multicentricity in breast cancer and survival outcomes. Ann Oncol 2012; 23:3063.</a></li><li class="breakAll">Breast Cancer. In: American Joint Committee on Cancer Cancer Staging Manual; 8th ed, 3rd printing, Amin MB, Edge SB, Greene FL, et al (Eds), Chicago 2018.</li><li><a class="nounderline abstract_t">Fisher B, Slack NH, Bross ID. Cancer of the breast: size of neoplasm and prognosis. Cancer 1969; 24:1071.</a></li><li><a class="nounderline abstract_t">Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63:181.</a></li><li><a class="nounderline abstract_t">Koscielny S, Tubiana M, Lê MG, et al. Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer 1984; 49:709.</a></li><li><a class="nounderline abstract_t">Pan H, Gray R, Braybrooke J, et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med 2017; 377:1836.</a></li><li><a class="nounderline abstract_t">Foulkes WD, Grainge MJ, Rakha EA, et al. Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. Breast Cancer Res Treat 2009; 117:199.</a></li><li><a class="nounderline abstract_t">Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67:7.</a></li><li><a class="nounderline abstract_t">Andersson Y, Frisell J, Sylvan M, et al. Breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes. J Clin Oncol 2010; 28:2868.</a></li><li><a class="nounderline abstract_t">de Boer M, van Dijck JA, Bult P, et al. Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases. J Natl Cancer Inst 2010; 102:410.</a></li><li><a class="nounderline abstract_t">Weaver DL, Ashikaga T, Krag DN, et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med 2011; 364:412.</a></li><li><a class="nounderline abstract_t">Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. Br J Cancer 2005; 93:1046.</a></li><li><a class="nounderline abstract_t">Pestalozzi BC, Zahrieh D, Mallon E, et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol 2008; 26:3006.</a></li><li><a class="nounderline abstract_t">Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19:403.</a></li><li><a class="nounderline abstract_t">Rakha EA, El-Sayed ME, Lee AH, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 2008; 26:3153.</a></li><li><a class="nounderline abstract_t">Pinder SE, Ellis IO, Galea M, et al. Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology 1994; 24:41.</a></li><li><a class="nounderline abstract_t">Ejlertsen B, Jensen MB, Rank F, et al. Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer. J Natl Cancer Inst 2009; 101:729.</a></li><li><a class="nounderline abstract_t">Viale G, Giobbie-Hurder A, Gusterson BA, et al. Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. Ann Oncol 2010; 21:245.</a></li><li><a class="nounderline abstract_t">Luporsi E, André F, Spyratos F, et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 2012; 132:895.</a></li><li><a class="nounderline abstract_t">de Azambuja E, Cardoso F, de Castro G Jr, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007; 96:1504.</a></li><li><a class="nounderline abstract_t">Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 2008; 17:323.</a></li><li><a class="nounderline abstract_t">Nielsen TO, Leung SCY, Rimm DL, et al. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 2021; 113:808.</a></li><li><a class="nounderline abstract_t">Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17:1474.</a></li><li><a class="nounderline abstract_t">Pertschuk LP, Kim DS, Nayer K, et al. Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival. Cancer 1990; 66:1663.</a></li><li><a class="nounderline abstract_t">Bartlett JM, Brookes CL, Robson T, et al. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol 2011; 29:1531.</a></li><li><a class="nounderline abstract_t">Colzani E, Liljegren A, Johansson AL, et al. Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics. J Clin Oncol 2011; 29:4014.</a></li><li><a class="nounderline abstract_t">Colleoni M, Sun Z, Price KN, et al. Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. J Clin Oncol 2016; 34:927.</a></li><li><a class="nounderline abstract_t">Insa A, Lluch A, Prosper F, et al. Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat 1999; 56:67.</a></li><li><a class="nounderline abstract_t">Ferrero-Poüs M, Trassard M, Le Doussal V, et al. Comparison of enzyme immunoassay and immunohistochemical measurements of estrogen and progesterone receptors in breast cancer patients. Appl Immunohistochem Mol Morphol 2001; 9:267.</a></li><li><a class="nounderline abstract_t">Chu KC, Anderson WF, Fritz A, et al. Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer 2001; 92:37.</a></li><li><a class="nounderline abstract_t">Knoop AS, Bentzen SM, Nielsen MM, et al. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 2001; 19:3376.</a></li><li><a class="nounderline abstract_t">Wenger CR, Beardslee S, Owens MA, et al. DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat 1993; 28:9.</a></li><li><a class="nounderline abstract_t">Falette N, Paperin MP, Treilleux I, et al. Prognostic value of P53 gene mutations in a large series of node-negative breast cancer patients. Cancer Res 1998; 58:1451.</a></li><li><a class="nounderline abstract_t">Elledge RM, Fuqua SA, Clark GM, et al. Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat 1993; 26:225.</a></li><li><a class="nounderline abstract_t">Andrulis IL, Bull SB, Blackstein ME, et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 1998; 16:1340.</a></li><li><a class="nounderline abstract_t">Tandon AK, Clark GM, Chamness GC, et al. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989; 7:1120.</a></li><li><a class="nounderline abstract_t">Ferrero-Poüs M, Hacène K, Bouchet C, et al. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis. Clin Cancer Res 2000; 6:4745.</a></li><li><a class="nounderline abstract_t">Bolla M, Chedin M, Souvignet C, et al. Estimation of epidermal growth factor receptor in 177 breast cancers: correlation with prognostic factors. Breast Cancer Res Treat 1990; 16:97.</a></li><li><a class="nounderline abstract_t">Pawlowski V, Révillion F, Hebbar M, et al. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000; 6:4217.</a></li><li><a class="nounderline abstract_t">Clark GM, McGuire WL, Hubay CA, et al. Progesterone receptors as a prognostic factor in Stage II breast cancer. N Engl J Med 1983; 309:1343.</a></li><li><a class="nounderline abstract_t">Purdie CA, Quinlan P, Jordan LB, et al. Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. Br J Cancer 2014; 110:565.</a></li><li><a class="nounderline abstract_t">Thakkar JP, Mehta DG. A review of an unfavorable subset of breast cancer: estrogen receptor positive progesterone receptor negative. Oncologist 2011; 16:276.</a></li><li><a class="nounderline abstract_t">Li Y, Yang D, Yin X, et al. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer. JAMA Netw Open 2020; 3:e1918160.</a></li><li><a class="nounderline abstract_t">Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992; 10:1049.</a></li><li><a class="nounderline abstract_t">Chia S, Norris B, Speers C, et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 2008; 26:5697.</a></li><li><a class="nounderline abstract_t">Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2015; 26:259.</a></li><li><a class="nounderline abstract_t">Banerji S, Cibulskis K, Rangel-Escareno C, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012; 486:405.</a></li><li><a class="nounderline abstract_t">Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486:346.</a></li><li><a class="nounderline abstract_t">Ding L, Ellis MJ, Li S, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010; 464:999.</a></li><li><a class="nounderline abstract_t">Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012; 486:353.</a></li><li><a class="nounderline abstract_t">Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012; 486:395.</a></li><li><a class="nounderline abstract_t">Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490:61.</a></li><li><a class="nounderline abstract_t">Leone JP, Graham N, Tolaney SM, et al. Estimating long-term mortality in women with hormone receptor-positive breast cancer: The 'ESTIMATE' tool. Eur J Cancer 2022; 173:20.</a></li><li class="breakAll">ESTIMATE tool. Available online at: estimatetool.org (Accessed on September 02, 2022).</li><li><a class="nounderline abstract_t">Dowsett M, Sestak I, Regan MM, et al. Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. J Clin Oncol 2018; 36:1941.</a></li><li><a class="nounderline abstract_t">Noordhoek I, Blok EJ, Meershoek-Klein Kranenbarg E, et al. Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials. J Clin Oncol 2020; 38:3273.</a></li><li><a class="nounderline abstract_t">Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12:R68.</a></li><li><a class="nounderline abstract_t">Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004; 203:661.</a></li><li><a class="nounderline abstract_t">Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747.</a></li><li><a class="nounderline abstract_t">Perreard L, Fan C, Quackenbush JF, et al. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res 2006; 8:R23.</a></li><li><a class="nounderline abstract_t">Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98:10869.</a></li><li><a class="nounderline abstract_t">Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100:8418.</a></li><li><a class="nounderline abstract_t">Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003; 100:10393.</a></li><li><a class="nounderline abstract_t">Yu K, Lee CH, Tan PH, Tan P. Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin Cancer Res 2004; 10:5508.</a></li><li><a class="nounderline abstract_t">Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27:1160.</a></li><li><a class="nounderline abstract_t">Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006; 355:560.</a></li><li><a class="nounderline abstract_t">Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7:96.</a></li><li><a class="nounderline abstract_t">Loi S, Haibe-Kains B, Desmedt C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007; 25:1239.</a></li><li><a class="nounderline abstract_t">Voduc KD, Cheang MC, Tyldesley S, et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010; 28:1684.</a></li><li><a class="nounderline abstract_t">Prat A, Chaudhury A, Solovieff N, et al. Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies. J Clin Oncol 2021; 39:1458.</a></li><li><a class="nounderline abstract_t">O'Brien KM, Cole SR, Tse CK, et al. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 2010; 16:6100.</a></li><li><a class="nounderline abstract_t">Schettini F, Pascual T, Conte B, et al. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treat Rev 2020; 84:101965.</a></li><li><a class="nounderline abstract_t">Cheang MC, Martin M, Nielsen TO, et al. Defining breast cancer intrinsic subtypes by quantitative receptor expression. Oncologist 2015; 20:474.</a></li><li><a class="nounderline abstract_t">Carey LA, Berry DA, Cirrincione CT, et al. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. J Clin Oncol 2016; 34:542.</a></li><li><a class="nounderline abstract_t">Llombart-Cussac A, Cortés J, Paré L, et al. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol 2017; 18:545.</a></li><li><a class="nounderline abstract_t">Teschendorff AE, Miremadi A, Pinder SE, et al. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007; 8:R157.</a></li><li><a class="nounderline abstract_t">Lehmann BD, Jovanović B, Chen X, et al. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One 2016; 11:e0157368.</a></li><li><a class="nounderline abstract_t">Stephens RW, Brünner N, Jänicke F, Schmitt M. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat 1998; 52:99.</a></li><li><a class="nounderline abstract_t">Harbeck N, Kates RE, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 2002; 20:1000.</a></li><li><a class="nounderline abstract_t">Malmström P, Bendahl PO, Boiesen P, et al. S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. J Clin Oncol 2001; 19:2010.</a></li><li><a class="nounderline abstract_t">Foekens JA, Peters HA, Look MP, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000; 60:636.</a></li><li><a class="nounderline abstract_t">Chappuis PO, Dieterich B, Sciretta V, et al. Functional evaluation of plasmin formation in primary breast cancer. J Clin Oncol 2001; 19:2731.</a></li><li><a class="nounderline abstract_t">Harris LN, Ismaila N, McShane LM, et al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016; 34:1134.</a></li><li><a class="nounderline abstract_t">Jänicke F, Prechtl A, Thomssen C, et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001; 93:913.</a></li><li><a class="nounderline abstract_t">Harbeck N, Schmitt M, Meisner C, et al. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer 2013; 49:1825.</a></li><li><a class="nounderline abstract_t">Thomssen C, Harbeck N, Dittmer J, et al. Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens. J Natl Cancer Inst 2009; 101:1028.</a></li><li><a class="nounderline abstract_t">Visscher DW, Sarkar F, LoRusso P, et al. Immunohistologic evaluation of invasion-associated proteases in breast carcinoma. Mod Pathol 1993; 6:302.</a></li><li><a class="nounderline abstract_t">Petitjean A, Achatz MI, Borresen-Dale AL, et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007; 26:2157.</a></li><li><a class="nounderline abstract_t">Bonnefoi H, Piccart M, Bogaerts J, et al. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol 2011; 12:527.</a></li><li><a class="nounderline abstract_t">Olivier M, Langerød A, Carrieri P, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 2006; 12:1157.</a></li><li><a class="nounderline abstract_t">Leyland-Jones B, Smith BR. Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls. Lancet Oncol 2011; 12:286.</a></li><li><a class="nounderline abstract_t">Tuck AB, O'Malley FP, Singhal H, et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 1998; 79:502.</a></li><li><a class="nounderline abstract_t">Heimann R, Hellman S. Individual characterisation of the metastatic capacity of human breast carcinoma. Eur J Cancer 2000; 36:1631.</a></li><li><a class="nounderline abstract_t">Heimann R, Lan F, McBride R, Hellman S. Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin. Cancer Res 2000; 60:298.</a></li><li><a class="nounderline abstract_t">Heimann R, Ferguson DJ, Hellman S. The relationship between nm23, angiogenesis, and the metastatic proclivity of node-negative breast cancer. Cancer Res 1998; 58:2766.</a></li><li><a class="nounderline abstract_t">Yu H, Levesque MA, Clark GM, Diamandis EP. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. Br J Cancer 1999; 81:490.</a></li><li><a class="nounderline abstract_t">Remacle A, McCarthy K, Noël A, et al. High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer 2000; 89:118.</a></li><li><a class="nounderline abstract_t">Ueno T, Toi M, Koike M, et al. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer 2000; 83:164.</a></li><li><a class="nounderline abstract_t">Yoshida R, Kimura N, Harada Y, Ohuchi N. The loss of E-cadherin, alpha- and beta-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer. Int J Oncol 2001; 18:513.</a></li><li><a class="nounderline abstract_t">Lipton A, Ali SM, Leitzel K, et al. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer. Cancer 2007; 109:1933.</a></li><li><a class="nounderline abstract_t">Emi M, Yoshimoto M, Sato T, et al. Allelic loss at 1p34, 13q12, 17p13.3, and 17q21.1 correlates with poor postoperative prognosis in breast cancer. Genes Chromosomes Cancer 1999; 26:134.</a></li><li><a class="nounderline abstract_t">Utada Y, Emi M, Yoshimoto M, et al. Allelic loss at 1p34-36 predicts poor prognosis in node-negative breast cancer. Clin Cancer Res 2000; 6:3193.</a></li><li><a class="nounderline abstract_t">Hui R, Macmillan RD, Kenny FS, et al. INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res 2000; 6:2777.</a></li><li><a class="nounderline abstract_t">Yang X, Yan L, Davidson NE. DNA methylation in breast cancer. Endocr Relat Cancer 2001; 8:115.</a></li><li><a class="nounderline abstract_t">Lipsyc-Sharf M, de Bruin EC, Santos K, et al. Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. J Clin Oncol 2022; 40:2408.</a></li><li><a class="nounderline abstract_t">Gerber B, Krause A, Müller H, et al. Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J Clin Oncol 2001; 19:960.</a></li><li><a class="nounderline abstract_t">Bidard FC, Vincent-Salomon A, Gomme S, et al. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin Cancer Res 2008; 14:3306.</a></li><li><a class="nounderline abstract_t">Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353:793.</a></li><li><a class="nounderline abstract_t">Janni W, Vogl FD, Wiedswang G, et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis. Clin Cancer Res 2011; 17:2967.</a></li><li><a class="nounderline abstract_t">Giuliano AE, Hawes D, Ballman KV, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA 2011; 306:385.</a></li><li><a class="nounderline abstract_t">Falck AK, Bendahl PO, Ingvar C, et al. Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study. BMC Cancer 2012; 12:403.</a></li><li><a class="nounderline abstract_t">Krishnamurthy S, Cristofanilli M, Singh B, et al. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer 2010; 116:3330.</a></li><li><a class="nounderline abstract_t">Hartkopf AD, Taran FA, Wallwiener M, et al. Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis. Eur J Cancer 2014; 50:2550.</a></li><li><a class="nounderline abstract_t">Lucci A, Hall CS, Lodhi AK, et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 2012; 13:688.</a></li><li><a class="nounderline abstract_t">Rack B, Schindlbeck C, Jückstock J, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst 2014; 106.</a></li><li><a class="nounderline abstract_t">Trapp E, Janni W, Schindlbeck C, et al. Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. J Natl Cancer Inst 2019; 111:380.</a></li><li><a class="nounderline abstract_t">Sparano J, O'Neill A, Alpaugh K, et al. Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 2018; 4:1700.</a></li><li><a class="nounderline abstract_t">Matikas A, Kotsakis A, Apostolaki S, et al. Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer. Br J Cancer 2022; 126:1563.</a></li><li><a class="nounderline abstract_t">Xenidis N, Perraki M, Kafousi M, et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 2006; 24:3756.</a></li><li><a class="nounderline abstract_t">Garcia-Murillas I, Chopra N, Comino-Méndez I, et al. Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. JAMA Oncol 2019; 5:1473.</a></li><li><a class="nounderline abstract_t">Pierga JY, Bidard FC, Mathiot C, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 2008; 14:7004.</a></li><li><a class="nounderline abstract_t">Wong NS, Kahn HJ, Zhang L, et al. Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients. Breast Cancer Res Treat 2006; 99:63.</a></li><li><a class="nounderline abstract_t">Ignatiadis M, Xenidis N, Perraki M, et al. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol 2007; 25:5194.</a></li><li><a class="nounderline abstract_t">Pachmann K, Camara O, Kavallaris A, et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol 2008; 26:1208.</a></li><li><a class="nounderline abstract_t">Merker JD, Oxnard GR, Compton C, et al. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol 2018; 36:1631.</a></li><li><a class="nounderline abstract_t">Pascual J, Attard G, Bidard FC, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol 2022; 33:750.</a></li></ol></div><div id="topicVersionRevision">Topic 782 Version 72.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22152853" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21802721" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22019144" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21924486" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8331681" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10066089" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22138009" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18813139" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21574648" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Biospecimen reporting for improved study quality (BRISQ).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15774793" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical trial designs for predictive marker validation in cancer treatment trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19815849" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Use of archived specimens in evaluation of prognostic and predictive biomarkers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1984541" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : NIH consensus conference. Treatment of early-stage breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17512856" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16087950" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15677625" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14679153" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25738668" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17954709" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15221370" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union--an inter-laboratory study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16236737" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16236738" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21991949" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Adjuvant trastuzumab in HER2-positive breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11248153" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23020162" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Trastuzumab emtansine for HER2-positive advanced breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22149875" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17159189" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28376219" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28692382" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29233559" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3736639" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The relation between survival and age at diagnosis in breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26976422" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23752109" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33371964" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : 10-Year Breast Cancer Outcomes in Women≤35 Years of Age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19907646" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Breast cancer in young women: poor survival despite intensive treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18612148" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27480155" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20428937" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16409108" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Differences in management of older women influence breast cancer survival: results from a population-based database in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22318280" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20519679" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23917289" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Characteristics associated with differences in survival among black and white women with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33983438" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Evaluation of Racial/Ethnic Differences in Treatment and Mortality Among Women With Triple-Negative Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26598753" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26371147" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16757721" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26811527" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cigarette Smoking Before and After Breast Cancer Diagnosis: Mortality From Breast Cancer and Smoking-Related Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15339900" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Risk for distant recurrence of breast cancer detected by mammography screening or other methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16106024" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Role of detection method in predicting breast cancer survival: analysis of randomized screening trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18506175" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22911616" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Relationship between mammographic density and breast cancer death in the Breast Cancer Surveillance Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20454925" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22776706" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Multifocality and multicentricity in breast cancer and survival outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22776706" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Multifocality and multicentricity in breast cancer and survival outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5353940" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Cancer of the breast: size of neoplasm and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2910416" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6733019" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29117498" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18600446" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28055103" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Cancer Statistics, 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20458033" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20190185" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21247310" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effect of occult metastases on survival in node-negative breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16175185" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Clinical characteristics of different histologic types of breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18458044" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1757079" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18490649" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Prognostic significance of Nottingham histologic grade in invasive breast carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8144141" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19436035" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19633051" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22048814" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17453008" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18455396" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33369635" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10334533" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2208020" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21422407" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21911717" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26786933" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10517344" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11556756" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Comparison of enzyme immunoassay and immunohistochemical measurements of estrogen and progesterone receptors in breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11443607" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11454885" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8123871" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9537247" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Prognostic value of P53 gene mutations in a large series of node-negative breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8251647" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Prognostic significance of p53 gene alterations in node-negative breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9552035" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2569032" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : HER-2/neu oncogene protein and prognosis in breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11156229" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2176111" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Estimation of epidermal growth factor receptor in 177 breast cancers: correlation with prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11106235" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6633596" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Progesterone receptors as a prognostic factor in Stage II breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24300977" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21339261" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A review of an unfavorable subset of breast cancer: estrogen receptor positive progesterone receptor negative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31899528" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1351538" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19001334" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25214542" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22722202" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Sequence analysis of mutations and translocations across breast cancer subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22522925" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20393555" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Genome remodelling in a basal-like breast cancer metastasis and xenograft.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22722193" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Whole-genome analysis informs breast cancer response to aromatase inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22495314" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : The clonal and mutational evolution spectrum of primary triple-negative breast cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23000897" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Comprehensive molecular portraits of human breast tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35841843" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Estimating long-term mortality in women with hormone receptor-positive breast cancer: The 'ESTIMATE' tool.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35841843" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Estimating long-term mortality in women with hormone receptor-positive breast cancer: The 'ESTIMATE' tool.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29676944" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32706636" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20813035" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15141381" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Expression of luminal and basal cytokeratins in human breast carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10963602" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Molecular portraits of human breast tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16626501" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11553815" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12829800" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Repeated observation of breast tumor subtypes in independent gene expression data sets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12917485" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Breast cancer classification and prognosis based on gene expression profiles from a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15328190" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19204204" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Supervised risk predictor of breast cancer based on intrinsic subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16899776" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Concordance among gene-expression-based predictors for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16643655" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : The molecular portraits of breast tumors are conserved across microarray platforms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17401012" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20194857" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Breast cancer subtypes and the risk of local and regional relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33769862" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21169259" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32000054" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25908555" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Defining breast cancer intrinsic subtypes by quantitative receptor expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26527775" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28238593" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17683518" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27310713" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10066075" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : The urokinase plasminogen activator system as a target for prognostic studies in breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11844823" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11283134" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10676647" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11352966" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Functional evaluation of plasmin formation in primary breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26858339" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11416112" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23490655" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19535782" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8346178" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Immunohistologic evaluation of invasion-associated proteases in breast carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17401424" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21570352" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16489069" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21376291" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9761120" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Osteopontin expression in a group of lymph node negative breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10959049" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Individual characterisation of the metastatic capacity of human breast carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10667580" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9661889" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : The relationship between nm23, angiogenesis, and the metastatic proclivity of node-negative breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10507775" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10756061" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : High levels of TIMP-2 correlate with adverse prognosis in breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10901365" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11179480" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : The loss of E-cadherin, alpha- and beta-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17407159" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10469451" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Allelic loss at 1p34, 13q12, 17p13.3, and 17q21.1 correlates with poor postoperative prognosis in breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10955803" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Allelic loss at 1p34-36 predicts poor prognosis in node-negative breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10914724" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11446343" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : DNA methylation in breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35658506" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11181658" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18519757" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16120859" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : A pooled analysis of bone marrow micrometastasis in breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21415211" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21791687" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22963449" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20564098" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Detection of minimal residual disease in blood and bone marrow in early stage breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25096167" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22677156" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Circulating tumour cells in non-metastatic breast cancer: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24832787" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Circulating tumor cells predict survival in early average-to-high risk breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30312434" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30054636" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35145253" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16769987" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31369045" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18980996" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16541316" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17954712" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18323545" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29504847" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35809752" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
